HSBC Overhauls European Pharma Ratings and Highlights AI Rotation Risk
HSBC Global Research released a comprehensive review of European pharmaceutical equities, adjusting target prices and ratings for several major companies while warning of sector‑wide capital‑intensity pressures and a potential rotation toward artificial‑intelligence‑driven businesses.
AstraZeneca plc saw its target price reduced to £165 from £172, with the broker maintaining a "buy" rating. The stock closed at 14,456 p on 3 July, indicating an implied upside of roughly 14.2 % to the new target. Concurrently, HSBC trimmed AstraZeneca’s revenue forecasts for 2026 and 2027 by 2.1 %.
GlaxoSmithKline plc (GSK) was upgraded from "reduce" to "hold", and its target price was raised to £18.60 from £15.00. The shares closed at 2,015 p on 3 July, representing an approximate 7.7 % upside to the revised target.
Roche Holding AG’s rating was cut from "buy" to "hold", with the target price left unchanged at CHF 365. Roche closed at CHF 346.20 on 3 July, implying about 5.4 % upside.
Merck KGaA also moved to a "hold" rating from "buy", but its target price was increased to €170 from €160. The stock finished at €145.65 on 3 July, suggesting an upside of roughly 16.7 %.
HSBC highlighted that the sector’s pipeline remains deep and that balance‑sheet capacity for acquisitions is still robust. However, the research flagged a patent‑cliff risk for GSK and noted that the catalysts for a de‑rating of the stock are limited. For Roche, the broker said that consensus estimates now better reflect pipeline revenue potential from giredestrant and fenebrutinib, removing the core of its previous bullish case.
The analyst team also discussed operational dynamics, stating that a recovery in Merck’s Process Solutions segment has been partially accelerated by supply‑chain destocking, and that difficult comps and further destocking are likely after the third quarter of 2026.
Regarding potential M&A, HSBC commented on the prospective acquisition of Bio‑Techne, describing the valuation as "rich" and suggesting that any returns would be accretive only in the most bullish scenarios.
Sanofi S.A. retained its "buy" rating with a target of €95. At a closing price of €75.81 on 3 July, the stock traded about 25.3 % below the target. HSBC noted that a partnership with Regeneron combined with possible further acquisitions could shift the narrative and drive a normalisation of multiples.
Bayer AG also kept a "buy" rating and a target of €60. The share price closed at €53.36 on 3 July, implying roughly 12.4 % upside, after an 8.90 % jump on 2 July following a Supreme Court verdict in Bayer’s favour. HSBC capped Bayer’s litigation liabilities at $7.25 billion.
Overall, HSBC’s review underscores a rotational risk toward AI‑focused investments, heightened capital‑intensity pressures, and a mixed outlook for European pharma stocks, balancing strong pipeline prospects against valuation concerns and sector‑specific headwinds.